The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial.

Ketan K DhatariyaStephen C BainJohn B BuseRichard SimpsonLise TarnowMargit Staum KaltoftMichael StellfeldKaren TornøeRichard E Pratleynull null

Published in: Diabetes care (2018)

Treatment with liraglutide in patients with type 2 diabetes and at high risk of CV events in the LEADER trial did not increase the risk of DFU events and was associated with a significantly lower risk of DFU-related amputations compared with placebo. This association, possibly due to chance, needs further investigation.

Keyphrases

cardiovascular events
phase iii
cardiovascular disease
study protocol
coronary artery disease
clinical trial
type diabetes
phase ii
risk factors
randomized controlled trial
double blind
glycemic control
drug induced
combination therapy
placebo controlled